Published in Nat Rev Cancer on August 01, 2003
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release (2008) 2.63
Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell (2004) 1.86
Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A (2005) 1.46
Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling. Mol Biol Cell (2005) 1.45
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem (2008) 1.33
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev (2006) 1.30
Vascular permeability and pathological angiogenesis in caveolin-1-null mice. Am J Pathol (2009) 1.26
Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med (2010) 1.25
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci U S A (2004) 1.21
Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci U S A (2004) 1.20
The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials (2009) 1.17
PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J (2010) 1.11
Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release (2014) 1.08
CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol Cell Biol (2005) 1.06
Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo. Circulation (2014) 1.05
Identification of astrocytoma associated genes including cell surface markers. BMC Cancer (2004) 1.04
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther (2011) 1.04
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Glycolipid transfer protein interaction with bilayer vesicles: modulation by changing lipid composition. Biophys J (2005) 1.03
Nanoparticles for combination drug therapy. ACS Nano (2013) 0.99
Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo. J Biol Chem (2009) 0.95
Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol (2005) 0.95
A hepatic sclerosed hemangioma with significant morphological change over a period of 10 years: a case report. J Med Case Rep (2013) 0.93
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance. Am J Cancer Res (2011) 0.91
The utilization of pathogen-like cellular trafficking by single chain block copolymer. Biomaterials (2009) 0.91
Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol (2011) 0.90
Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res (2010) 0.88
Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene. J Clin Endocrinol Metab (2011) 0.88
Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma (2012) 0.87
Caveolae-dependent and -independent uptake of albumin in cultured rodent pulmonary endothelial cells. PLoS One (2013) 0.86
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. World J Gastroenterol (2005) 0.84
Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues. Mol Cell Proteomics (2010) 0.84
Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med (2013) 0.84
Involvement of Caveolin-1 in repair of DNA damage through both homologous recombination and non-homologous end joining. PLoS One (2010) 0.83
Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation. Mol Cell Pharmacol (2015) 0.81
Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem (2014) 0.81
Revolutionary impact of nanodrug delivery on neuroscience. Curr Neuropharmacol (2012) 0.79
Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media. Cancer Res (2009) 0.79
Evidence for ectopic aerobic ATP production on C6 glioma cell plasma membrane. Cell Mol Neurobiol (2010) 0.79
Lesser-Known Molecules in Ovarian Carcinogenesis. Biomed Res Int (2015) 0.78
Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro. Int J Clin Exp Med (2015) 0.78
Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity. Int J Nanomedicine (2014) 0.77
Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension. Biomed Res Int (2015) 0.77
Delivery of Polymeric Nanoparticles to Target Vascular Diseases. J Biomol Res Ther (2014) 0.77
Targeted endothelial nanomedicine for common acute pathological conditions. J Control Release (2015) 0.77
A Role for the Cavin-3/Matrix Metalloproteinase-9 Signaling Axis in the Regulation of PMA-Activated Human HT1080 Fibrosarcoma Cell Neoplastic Phenotype. Cancer Growth Metastasis (2014) 0.77
Caveolae in fibroblast-like synoviocytes: static structures associated with vimentin-based intermediate filaments. Histochem Cell Biol (2008) 0.77
Caveolin-1 in the regulation of cell metabolism: a cancer perspective. Mol Cancer (2016) 0.76
Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. J Mol Diagn (2010) 0.76
The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer. Breast Cancer (Dove Med Press) (2010) 0.75
Albumen Transport to Bruch's Membrane and RPE by Choriocapillaris Caveolae. Invest Ophthalmol Vis Sci (2016) 0.75
The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells. Cell Death Dis (2017) 0.75
Cavin-2 Functions as a Suppressive Regulator in TNF-induced Mesenchymal Stromal Cell Inflammation and Angiogenic Phenotypes. Int J Stem Cells (2016) 0.75
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol (2004) 2.98
Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol (2003) 1.47
Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A (2005) 1.46
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol (2002) 1.21
Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.10
Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc Natl Acad Sci U S A (2009) 1.00
Enhancing identifications of lipid-embedded proteins by mass spectrometry for improved mapping of endothelial plasma membranes in vivo. Mol Cell Proteomics (2009) 0.99
Neutral sphingomyelinase inhibitor scyphostatin prevents and ceramide mimics mechanotransduction in vascular endothelium. Am J Physiol Heart Circ Physiol (2004) 0.97
Application of capture-recapture models to estimation of protein count in MudPIT experiments. Anal Chem (2006) 0.96
Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo. J Biol Chem (2009) 0.95
T cell pathways involving CTLA4 contribute to a model of acute lung injury. J Immunol (2010) 0.94
Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. Am J Physiol Lung Cell Mol Physiol (2009) 0.92
Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. J Biol Chem (2002) 0.90
Role of caveolae and lipid rafts in cancer: workshop summary and future needs. Cancer Res (2003) 0.90
Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging. Int J Nanomedicine (2010) 0.90
Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex. J Am Chem Soc (2013) 0.89
Genomics and proteomics of lung disease: conference summary. Am J Physiol Lung Cell Mol Physiol (2007) 0.88
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Endothelin induces rapid, dynamin-mediated budding of endothelial caveolae rich in ET-B. J Biol Chem (2012) 0.84
Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues. Mol Cell Proteomics (2010) 0.84
Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat. J Vasc Res (2009) 0.83
Caveolae and cancer. Recent Results Cancer Res (2010) 0.82
Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc (2009) 0.81
Chapter 8. Proteomic mapping of the vascular endothelium in vivo for vascular targeting. Methods Enzymol (2008) 0.79
Streamlining biomarker discovery. Nat Biotechnol (2011) 0.79
Laser-targeted photosensitizer-induced lung injury: noninvasive rat model of pulmonary infarction. Exp Lung Res (2011) 0.76
Range Charts for Agreement in Measurement Comparison Studies, With Application to Replicate Mass Spectrometry Experiments. J Proteomics Bioinform (2008) 0.76
Systems analysis of endothelial cell plasma membrane proteome of rat lung microvasculature. Proteome Sci (2011) 0.76
Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector. Virol J (2010) 0.75
Tumor targeting, trifunctional dendritic wedge. Bioconjug Chem (2014) 0.75
Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. Am J Physiol Heart Circ Physiol (2013) 0.75